PreveCeutical Medical Inc. PRVCF Archives

ThursdayOct 04, 2018 11:05 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Enters LOI to Acquire Penta 5 Group, Extensive Portfolio of Market-Ready Products

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) late Wednesday announced its entry into a letter of intent with Penta 5 Packaging Inc. and Penta 5 USA, LLC (together the “Penta 5 Group”) through which PreveCeutical intends to acquire the Penta 5 Group and its assets, including over 120 market-ready products and a 150,000-square-foot, state-of-the-art packaging facility. “The Transaction will significantly benefit PreveCeutical and its shareholders,” Stephen Van Deventer, chairman, CEO and president of PreveCeutical, stated in the news release. “The Penta 5 Group, led by R. Charles Murray, has recorded over 20 years of success…

WednesdayOct 03, 2018 12:33 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Partners with Asterion Cannabis to Develop Organic Cannabinoid Products

PreveCeutical Medical Inc. enters into a joint venture agreement with Asterion Cannabis Inc. to develop several nature-based cannabinoid products; the products will help the company respond to the demands for personalized and effective cannabis therapies The development agreement will see Asterion inject funds at cost, while PreveCeutical will contribute by way of opening its research resources, including personnel for use in the project The percentage ownership of intellectual and product rights from the agreement will be shared between Asterion and PreveCeutical in the ratio of 80 percent to 20 percent Since the agreement involves related parties including current and former…

WednesdaySep 26, 2018 10:33 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Announces Joint Venture Agreement with Asterion Cannabis Inc.

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its entry into an agreement to form a joint venture focused on the development of a range of medicinal cannabinoid products, including sublingual tablets, transdermal patches and other jointly evaluated products aimed at treating various ailments such as chronic pain, inflammation, epilepsy and anxiety disorders. “This agreement between PreveCeutical and Asterion further supports our mission to improve global health and healthcare by utilizing innovative science and cutting-edge technology to enhance natural products,” Stephen Van Deventer, chairman, CEO and president of PreveCeutical, stated in the news release.…

MondaySep 24, 2018 2:03 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) “Gets It Right” in Cannabinoid Extraction

Sol-gel nose-to-brain system offers superior drug delivery New extraction protocol makes accurate and precise quantification of cannabinoids possible Establishment of cannabis division to commercialize research developments A recent release from PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) shows that, in cannabinoid extraction technology, the health sciences company is getting it right. The company announced that, during its soluble gel drug delivery research and development program – the Sol-gel Program – it had successfully optimized the conditions for extracting cannabinoids from one of its cannabis strains and developed a proprietary method – the Extraction Protocol – for the accurate…

FridaySep 21, 2018 2:07 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Strategically Employs R&D Strategy to Achieve Increased Productivity

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) aims to give its investors more bang for their buck when it comes to research and development (“R&D”), as it has been proven that smaller companies achieve higher R&D productivity. A recent article discussing the company reads: “PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has taken this advice to heart. The health sciences company has three distinct research programs underway. Top of the line is a non-opioid pain treatment based on cannabinoids to be administered through a proprietary nose-to-brain, soluble gel (Sol-gel) drug delivery system. The research…

MondaySep 17, 2018 12:08 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Building on Key Milestones in Sol-gel Cannabinoid Development

Cannabinoid molecule extraction, quantification mark early successes in PreveCeutical’s drug delivery development process PreveCeutical optimistic about prototypical spray applicators in development for cannabinoid therapies Clinical trials of cannabis-based therapeutics anticipated next year PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is celebrating the achievement of several key milestones in the development of the company’s proprietary Sol-gel program for the nasal delivery of select medications, where those medications can be expected to effectively reach the nervous system in order to accomplish their purposes in treating conditions ranging from anxiety to head concussion injuries, a company officer told market reporting outlet…

FridaySep 14, 2018 11:26 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Advances Nature Identical Peptides Testing

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is steadfast in its mission of developing preventive therapies for health-conscious consumers who want nature-based products. A recent article discussing the company reads, “In recent months, the company has advanced the testing of its Nature Identical™ peptides toward the treatment and prevention of cancers such as the glioblastoma, the disease that took the life of Sen. John McCain. The company’s research team identified eight peptide candidates for the anticipated line of wellness products earlier this year, building on analysis of the Caribbean blue scorpion whose venom is widely reputed…

ThursdaySep 06, 2018 10:11 am

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Deploys Winning R&D Strategy

Smaller companies achieve higher R&D productivity Collaboration with academia key to R&D success Diverse projects increase chance of success Big Pharma is losing the game in drug development. A decade ago, McKinsey & Company sounded the alarm, warning that the biopharma industry was afflicted by “diminishing R&D productivity.” Despite a doubling of investment in research and development, approvals of “new molecular entities” had fallen precipitously (http://ibn.fm/jUNpt). Nothing appears to have changed since then. A recent report by Deloitte laments the continued decline of returns on R&D investment. While R&D costs have generally remained the same, product revenues are falling, in part…

TuesdaySep 04, 2018 11:39 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Develops Proprietary Cannabinoid Extraction Protocol

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) today announced that it has successfully optimized its extraction protocol during its soluble gel ("Sol-gel") drug delivery research and development program. The company augmented the circumstances for extracting cannabinoids from one of its cannabis strains and established a proprietary method for the accurate quantification of cannabinoids present in the extract. The accuracy and precision of the company’s extraction protocol was confirmed against eight commercial cannabinoid standards over a wide concentration range. PreveCeutical anticipates that the new protocol will accelerate the creation of a library of chemically fingerprinted cannabinoid extracts.…

FridayAug 31, 2018 11:04 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Developmental Pipeline Houses Comprehensive Range of Advanced Therapeutic Products

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) holds a wide array of advanced therapeutic products in its development pipeline, including its Sol-gel delivery platform. The Sol-gel nose-to-brain drug delivery platform delivers a therapeutic compound to a targeted site at a deliberate, controlled rate. A recent article further discussing the company reads: “The Sol-gel platform allows a therapeutic agent to be administered via the nostrils, where it changes rapidly to a gel upon contact with mucosal tissue. The gel, which continues to line the nasal passage for up to seven days, slowly releases the therapeutic agent over…

Site Search

Company Search

Tag: PreveCeutical Medical Inc. PRVCF